AbbVie Acquisition +4.5%: AbbVie Bets Big on Apogee
Is AbbVie’s $10.9 billion Apogee deal a bold immunology masterstroke, or an expensive bet on future growth? Maik Kemper Editor in Chief The acquisition of Apogee further builds…
Eli Lilly Acquisition $3.8B Push Opens Vaccine Growth Lane
Can Eli Lilly turn obesity cash into its next blockbuster by spending $3.83 billion on vaccines? Maik Kemper Editor in Chief The deals reflect a deliberate strategy to…